Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.02B | $1.03B | $1.66B | $1.63B | $1.99B | $2.09B | $2.21B | $2.39B | $2.79B | $3.02B |
| Revenue growth | — | 1.5% | 60.9% | -2.2% | 22.5% | 5.1% | 5.7% | 8.2% | 16.7% | 8.0% |
| Gross profit | $597M | $526M | $716M | $353M | $628M | $769M | $785M | $821M | $1.02B | $1.11B |
| Gross margin | 58.7% | 50.9% | 43.1% | 21.7% | 31.5% | 36.7% | 35.5% | 34.3% | 36.5% | 36.9% |
| Operating income | $285M | $245M | -$19.7M | -$249M | $91.2M | $153M | -$94.9M | $204M | $249M | $394M |
| Operating margin | 28.0% | 23.7% | -1.2% | -15.3% | 4.6% | 7.3% | -4.3% | 8.5% | 8.9% | 13.1% |
| Net income | $0.00 | $0.00 | -$19.7M | -$604M | $67.8M | $13.2M | -$271M | -$84.0M | -$117M | $72.1M |
| Net margin | 0.0% | 0.0% | -1.2% | -37.1% | 3.4% | 0.6% | -12.2% | -3.5% | -4.2% | 2.4% |
| EPS (diluted) | — | — | -$0.16 | -$2.74 | $0.61 | $0.07 | -$0.86 | -$0.48 | -$0.38 | $0.22 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $115M | $234M | $250M | $1.71M | $379M | $242M | $65.1M | $346M | $295M | $340M |
| Capital expenditures | $123M | $94.8M | $83.1M | $47.2M | $56.4M | $47.7M | $46.4M | $43.2M | $51.9M | $70.1M |
| Free cash flow | -$7.70M | $139M | $167M | -$45.5M | $323M | $194M | $18.7M | $302M | $243M | $270M |
| Dividends paid | $201M | $375M | $183M | $0.00 | $0.00 | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $27.4M | $74.2M | $213M | $151M | $341M | $248M | $26.0M | $91.5M | $111M | $282M |
| Total assets | — | $1.34B | $4.35B | $3.67B | $4.01B | $3.94B | $3.80B | $3.47B | $3.50B | $3.68B |
| Total liabilities | — | $0.00 | — | — | — | — | — | — | — | — |
| Long-term debt | — | $1.36B | $2.63B | $2.61B | $2.74B | $2.68B | $2.59B | $2.39B | $2.16B | $2.57B |
| Shareholders' equity | — | $0.00 | $505M | $232M | $303M | $360M | $298M | $19.8M | -$109M | -$70.8M |
| Retained earnings | — | -$383M | -$20.9M | -$378M | -$287M | -$276M | -$406M | -$490M | -$607M | -$535M |
| Shares (wtd avg diluted) | — | 1.00B | 127M | 132M | 149M | 152M | 151M | 176M | 309M | 325M |
Every figure is extracted from Amneal Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.